Boehringer Ingelheim announced today that it inaugurated a biomass powerplant at its Ingelheim, Germany site. The pharmaceutical company — one of the largest in the world — opened the new plant to optimize its energy supply and protect the environment. With the new plant, the company expects to save around 50,000 tons of CO2. It…

Boehringer Ingelheim (Ingelheim, Germany) has teamed up with the prescription drug pricing tracker GoodRx (NSDQ:GDRX) to facilitate patients’ access to cost savings. For instance, people with type 2 diabetes or chronic obstructive pulmonary disease (COPD) can use GoodRx to enroll in copay programs for relevant Boehringer Ingelheim drugs. The two companies estimate that the alliance…

Nanoparticle medicine specialist Nanoform (Helsinki, Finland) and Boehringer Ingelheim (Ingelheim am Rhein, Germany) will collaborate on proof-of-concept studies related to Nanoform’s CESS technology. The master services agreement enables the two parties to move forward with pre-clinical research related to CESS, an acronym for “Controlled Expansion of Supercritical Solutions.” CESS has the potential to optimize the…

Environmental monitoring software developer Novatek (Quebec, Canada) has extended its partnership with Boehringer Ingelheim. In particular, Novatek has announced that it has won reapproval from the drugmaker to use its software in its human pharma, animal health and biopharmaceutical aseptic (sterile) manufacturing sites internationally. “We are excited to announce that Novatek is requalified as an approved supplier…

Boehringer Ingelheim has reached an agreement in principle to settle some 2,935 lawsuits tied to its blood thinner Pradaxa (dabigatran etexilate).  In a Connecticut Supreme Court filing, privately owned Boehringer (Ingelheim am Rhein, Germany) stated the settlement would resolve the lawsuits, which alleged the anticoagulant drug Pradaxa caused undisclosed bleeding risks. The company expects it will…